Neurocrine Biosciences Posts 44% Revenue Surge, Eyes $2.9B Soleno Acquisition
Event summary
- Neurocrine Biosciences reported $811M in Q1 2026 net product sales, up 44% YoY, driven by INGREZZA and CRENESSITY growth.
- Company agreed to acquire Soleno Therapeutics for $2.9B, adding VYKATTM XR for Prader-Willi syndrome treatment.
- Launched Phase 2 study for NBI-1117570 in schizophrenia and Phase 1 study for NBIP-'2118 in obesity.
- Reaffirmed 2026 INGREZZA sales guidance of $2.7B-$2.8B despite lower net pricing.
The big picture
Neurocrine's strong Q1 performance and strategic acquisition reflect its aggressive push into rare disease and endocrinology markets. The $2.9B Soleno deal expands its portfolio while the company's robust pipeline positions it for sustained growth. The biopharmaceutical sector continues to see consolidation as companies seek to bolster their offerings in high-need therapeutic areas.
What we're watching
- Integration Challenges
- Whether Neurocrine can successfully integrate Soleno Therapeutics and realize expected synergies by Q2 2026.
- Pipeline Progress
- The pace at which NBI-1117570 and NBIP-'2118 advance through clinical trials will determine Neurocrine's long-term growth prospects.
- Market Positioning
- How the addition of VYKATTM XR will strengthen Neurocrine's leadership in endocrinology and rare disease markets.
Related topics